表紙
市場調查報告書

美國的惡性血液疾病檢驗市場:各產品、疾病、技術、終端用戶、各國資料,競爭環境 - 分析與預測(2018∼2025年)

U.S. Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Country Data and Competitive Landscape - Analysis and Forecast, 2018-2025

出版商 BIS Research Inc. 商品編碼 930642
出版日期 內容資訊 英文 230 Pages
商品交期: 最快1-2個工作天內
價格
美國的惡性血液疾病檢驗市場:各產品、疾病、技術、終端用戶、各國資料,競爭環境 - 分析與預測(2018∼2025年) U.S. Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Country Data and Competitive Landscape - Analysis and Forecast, 2018-2025
出版日期: 2020年03月09日內容資訊: 英文 230 Pages
簡介

美國的惡性血液疾病檢驗市場,至2025年預計將達到18億2,700萬美元。該市場2019∼2025年間預測將以年複合成長率14.60%擴大。惡性血液疾病的發病率上升,有利的償付方案,市場的增資是主要的促進要素,不過,專家培養和價格急劇上升,遺傳基因檢驗的分析學的有效性的問題等,也是阻礙市場成長的要素。

本報告提供美國的惡性血液疾病檢驗市場相關調查,市場趨勢,市場佔有率預測,競爭趨勢,各市場區隔趨勢,參與企業的簡介等相關資訊彙整。

第1章 產品定義

第2章 市場範圍

第3章 調查方法

第4章 美國的惡性血液疾病的流行病學

第5章 銷售量資料

第6章 市場趨勢

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會

第7章 競爭環境

  • 策略與發展
  • 產品方案
  • 融資方案
  • 市場佔有率分析
  • 成長佔有率分析

第8章 產業見解

第9章 各產品市場

  • 服務
  • 套件

第10章 各終端用戶市場

  • 專門診所,醫院
  • 診斷測試所
  • 參照實驗室
  • 研究機關

第11章 各疾病市場

  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 骨髓增生性疾病
  • 骨髓發育不良症候群

第12章 各技術市場

  • 次世代定序
  • 聚合酵素鏈鎖反應(PCR)
  • 螢光In-Situ混合化(FISH)
  • 免疫組織化學(IHC)
  • 流式細胞技術
  • 其他技術

第13章 企業簡介

目錄
Product Code: BH201A

U.S. Hematologic Malignancies Market to Reach $1,827 Million by 2025

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the U.S. hematologic malignancies testing market?
  • What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
  • Which is the dominant product type developed by the leading and emerging players for the diagnosis of hematologic malignancies?
  • What are the key technologies that have been used by leading players in the U.S. market for the development of diagnostic solutions for hematologic malignancies?
  • How each segment of the market is expected to grow during the forecast period from 2019 to 2025 based on:
    • product type
    • disease
    • technology
    • end user
    • country, i.e., U.S.
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the reimbursement scenario and the regulations for the development of diagnostic solutions for the diagnosis of hematologic malignancies, specifically in the U.S.?

U.S. Hematologic Malignancies Market Forecast

The U.S. hematologic malignancies market analysis by BIS Research projects the market to grow at a significant CAGR of 14.60% during the forecast period, 2019-2025. The U.S. hematologic malignancies market generated $723.9 million revenue in 2018, in terms of value.

The U.S. hematologic malignancies market growth has been primarily attributed to the major drivers in this market, such as rising incidence of hematologic malignancies, favorable reimbursement scenario, and increase in funding in the hematologic malignancies market. However, there are factors hindering the growth of the market, such as lack of training professionals, high pricing pressure, and issue pertaining to the analytic validity of genetic testing.

Expert Quote

"In an era of precision and increasingly personalized therapy, the healthcare industry demands cost-effective options that can robustly identify biomarkers to help select cancer patients most likely to benefit from the emerging class of immuno-oncology drug."

Scope of the Market Intelligence on the U.S. Hematologic Malignancies Market

The U.S. hematologic malignancies market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with industrial and biological research. In addition, the study also includes exhaustive information on unmet needs, perception on new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the U.S. hematologic malignancies market.

Market Segmentation

  • The U.S. hematologic malignancies market (on the basis of product type) is segmented into kits and services.
  • The U.S. hematologic malignancies market (on the basis of technology) is segmented into polymerase chain reaction, next-generation sequencing, fluorescence in-situ hybridization, immunohistochemistry, flow-cytometry, and other technologies.
  • The U.S. hematologic malignancies market (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.
  • The U.S. hematologic malignancies market (on the basis of end user) is segmented into specialty clinics and hospitals, research institutions, reference laboratories, diagnostic laboratories, and other end users.

Key Companies in the U.S. Hematologic Malignancies Market

The key manufacturers that have been contributing significantly to the U.S. hematologic malignancies market includes Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Corporation, Cancer Genetics Inc., QIAGEN N.V., ICON plc, Quest Diagnostics Incorporated, Invitae Corporation, Opkp Health, Laboratory Corporation of American Holdings, NeoGenomics Laboratories, Inc., ASURAGEN, INC., ArcherDX, Inc., Adaptive Biotechnologies, ARUP Laboratories, and Invivoscribe, Inc, among others.

TABLE OF CONTENTS

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 U.S. Hematologic Malignancies Testing Market: Research Methodology
  • 3.2 Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Epidemiology of Hematological Malignancies in U.S.

5 U.S. Hematologic Malignancies Testing Market: Value and Volume Data 2019 (U.S. State Regions)

  • 5.1 Midwest U.S.
  • 5.2 Mid Atlantic
  • 5.3 The Southwest
  • 5.4 New England
  • 5.5 The West
  • 5.6 The South

6 Market Dynamics

  • 6.1 Market Drivers
    • 6.1.1 Rising Incidence of Hematologic Malignancies
    • 6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
    • 6.1.3 Favorable Reimbursement Scenario in the U.S. hematologic Malignancies Testing Market
    • 6.1.4 Increase in Funding in Hematologic Malignancies Testing Market
  • 6.2 Restraints
    • 6.2.1 High Pricing Pressure
    • 6.2.2 Lack of Trained Professionals
    • 6.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers
  • 6.3 U.S. Market Opportunities
    • 6.3.1 An Underlying Relaxation in Revised 2018 PAMA Criteria
    • 6.3.2 Informatics and Technological Innovation for Larger Consumer Base
    • 6.3.3 Technological Advancements in the Field of Molecular Diagnostics

7 Competitive Landscape

  • 7.1 Key Strategies and Developments
    • 7.1.1 Synergistic Activities
    • 7.1.2 Approvals
    • 7.1.3 Product Launches and Enhancements
    • 7.1.4 Merger, Acquisitions & Expansions
  • 7.2 Product Scenario
  • 7.3 Funding Scenario
  • 7.4 Market Share Analysis
  • 7.5 Growth Share Analysis (Opportunity Mapping)
    • 7.5.1 By Company
    • 7.5.2 By Product

8 Industry Insights

  • 8.1 Regulatory Framework
    • 8.1.1 Legal Requirements and Framework in the U.S.
  • 8.2 Reimbursement Scenario
    • 8.2.1 Protecting Access to Medicare Act (PAMA) Criteria for Advanced Diagnostic Laboratory Tests (ADLT)
  • 8.3 Physicians' Perceptions

9 U.S. Hematologic Malignancies Testing Market (by Product) 2018-2025 ($ Million)

  • 9.1 Services
  • 9.2 Kits
    • 9.2.1 NGS-Based Gene Panels
      • 9.2.1.1 Leukemia
      • 9.2.1.2 Lymphoma
      • 9.2.1.3 Multiple Myeloma
      • 9.2.1.4 Myeloproliferative Neoplasms
      • 9.2.1.5 Myelodysplastic Syndromes
    • 9.2.2 NGS-Based Molecular Clonality Testing
      • 9.2.2.1 Leukemia
      • 9.2.2.2 Lymphoma
      • 9.2.2.3 Multiple Myeloma
      • 9.2.2.4 Myeloproliferative Neoplasms
      • 9.2.2.5 Myelodysplastic Syndromes
    • 9.2.3 NGS-Based Translocation Testing
      • 9.2.3.1 Leukemia
      • 9.2.3.2 Lymphoma
      • 9.2.3.3 Multiple Myeloma
      • 9.2.3.4 Myeloproliferative Neoplasms
      • 9.2.3.5 Myelodysplastic Syndromes
    • 9.2.4 NGS-Based Mutation Testing
      • 9.2.4.1 Leukemia
      • 9.2.4.2 Lymphoma
      • 9.2.4.3 Multiple Myeloma
      • 9.2.4.4 Myeloproliferative Neoplasms
      • 9.2.4.5 Myelodysplastic Syndromes
    • 9.2.5 NGS-Based Minimal Residual Disease (MRD) Testing
      • 9.2.5.1 Leukemia
      • 9.2.5.2 Lymphoma
      • 9.2.5.3 Multiple Myeloma
      • 9.2.5.4 Myeloproliferative Neoplasms
      • 9.2.5.5 Myelodysplastic Syndromes

10 U.S. Hematologic Malignancies Testing Market (by End User)

  • 10.1 Specialty Clinics and Hospitals
  • 10.2 Diagnostic Laboratories
  • 10.3 Reference Laboratories
  • 10.4 Research Institutions

11 U.S. Hematologic Malignancies Testing Market (by Disease)

  • 11.1 Leukemia
  • 11.2 Lymphoma
  • 11.3 Multiple Myeloma
  • 11.4 Myeloproliferative Neoplasms
  • 11.5 Myelodysplastic Syndromes

12 U.S. Hematologic Malignancies Testing Market (by Technology)

  • 12.1 Next-generation Sequencing (NGS)
  • 12.2 Polymerase Chain Reaction (PCR)
  • 12.3 Fluorescence In-Situ Hybridization (FISH)
  • 12.4 Immunohistochemistry (IHC)
  • 12.5 Flow Cytometry
  • 12.6 Other Technologies

13 Company Profiles

  • 13.1 Overview
  • 13.2 Abbott Laboratories
    • 13.2.1 Company Overview
    • 13.2.2 Role of Abbott Laboratories in the U.S. Hematologic Malignancies Testing Market
    • 13.2.3 Financials
    • 13.2.4 Key Insights About Financial Health of the Company
    • 13.2.5 SWOT Analysis
  • 13.3 Illumina, Inc.
    • 13.3.1 Company Overview
    • 13.3.2 Role of Illumina, Inc. in the U.S. Hematologic Malignancies Testing Market
    • 13.3.3 Financials
    • 13.3.4 Key Insights About Financial Health of the Company
    • 13.3.5 SWOT Analysis
  • 13.4 F. Hoffmann-La Roche Ltd
    • 13.4.1 Company Overview
    • 13.4.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Hematologic Malignancies Testing Market
    • 13.4.3 Financials
    • 13.4.4 Key Insights About Financial Health of the Company
    • 13.4.5 SWOT Analysis
  • 13.5 Bio-Rad Laboratories, Inc.
    • 13.5.1 Company Overview
    • 13.5.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Hematologic Malignancies Testing Market
    • 13.5.3 Financials
    • 13.5.4 Key Insights About Financial Health of the Company
    • 13.5.5 SWOT Analysis
  • 13.6 Sysmex Corporation
    • 13.6.1 Company Overview
    • 13.6.2 Role of Sysmex Corporation in the U.S. hematologic Malignancies Testing Market
    • 13.6.3 Financials
    • 13.6.4 Key Insights About Financial Health of the Company
    • 13.6.5 SWOT Analysis
  • 13.7 ASURAGEN, INC.
    • 13.7.1 Company Overview
    • 13.7.2 Role of ASURAGEN, INC. in the U.S. Hematologic Malignancies Testing Market
    • 13.7.3 SWOT Analysis
  • 13.8 Cancer Genetics Inc.
    • 13.8.1 Company Overview
    • 13.8.2 Role of Cancer Genetics Inc.in the U.S. Hematologic Malignancies Testing Market
    • 13.8.3 Financials
    • 13.8.4 Key Insights About Financial Health of the Company
    • 13.8.5 SWOT Analysis
  • 13.9 QIAGEN N.V.
    • 13.9.1 Company Overview
    • 13.9.2 Role of QIAGEN N.V. in the U.S. Hematologic Malignancies Testing Market
    • 13.9.3 Financials
    • 13.9.4 Key Insights about Financial Health of the Company
    • 13.9.5 SWOT Analysis
  • 13.10 ArcherDX, Inc.
    • 13.10.1 Company Overview
    • 13.10.2 Role of ArcherDX, Inc. in the U.S. Hematologic Malignancies Testing Market
    • 13.10.3 SWOT Analysis
  • 13.11 Adaptive Biotechnologies
    • 13.11.1 Company Overview
    • 13.11.2 Role of Adaptive Biotechnologies in the U.S. Hematologic Malignancies Testing Market
    • 13.11.3 SWOT Analysis
  • 13.12 ICON plc
    • 13.12.1 Company Overview
    • 13.12.2 Role of ICON plc in the U.S. Hematologic Malignancies Testing Market
    • 13.12.3 Financials
    • 13.12.4 SWOT Analysis
  • 13.13 Quest Diagnostics Incorporated
    • 13.13.1 Company Overview
    • 13.13.2 Role of Quest Diagnostics Limited in the U.S. Hematologic Malignancies Testing Market
    • 13.13.3 Financials
    • 13.13.4 SWOT Analysis
  • 13.14 ARUP Laboratories
    • 13.14.1 Company Overview
    • 13.14.2 Role of ARUP Laboratories in the U.S. Hematologic Malignancies Testing Market
    • 13.14.3 SWOT Analysis
  • 13.15 Invivoscribe, Inc.
    • 13.15.1 Company Overview
    • 13.15.2 Role of Invivoscribe, Inc. in the U.S. Hematologic Malignancies Testing Market
    • 13.15.3 SWOT Analysis
  • 13.16 NeoGenomics Laboratories, Inc.
    • 13.16.1 Company Overview
    • 13.16.2 Role of NeoGenomics Laboratories, Inc. in the U.S. hematologic malignancies testing Market
    • 13.16.3 Financials
    • 13.16.4 Key Insights about Financial Health of the Company
    • 13.16.5 SWOT Analysis
  • 13.17 Invitae Corporation
    • 13.17.1 Company Overview
    • 13.17.2 Role of Invitae Corporation, Inc. in the U.S. hematologic malignancies testing Market
    • 13.17.3 Financials
    • 13.17.4 Key Insights about Financial Health of the Company
    • 13.17.5 SWOT Analysis
  • 13.18 Opko Health
    • 13.18.1 Company Overview
    • 13.18.2 Role of Opko Health, Inc. in the U.S. hematologic malignancies testing Market
    • 13.18.3 Financials
    • 13.18.4 Key Insights about Financial Health of the Company
    • 13.18.5 SWOT Analysis
  • 13.19 Laboratory Corporation of America Holdings
    • 13.19.1 Company Overview
    • 13.19.2 Role of Laboratory Corporation of America Holdings in the U.S. Hematologic Malignancies Market
    • 13.19.3 Financials
    • 13.19.4 SWOT Analysis

List of Tables

  • Table 7.1: Market Players with Key Product Listing
  • Table 8.1: Reimbursement Coverage
  • Table 8.2: Key Coverage Providers for Hematologic Malignancies Testing
  • Table 9.1: Product Portfolio: NGS-Based Gene Panels
  • Table 9.2: Product Portfolio: NGS-Based Molecular Clonality Testing
  • Table 9.3: Product Portfolio: NGS-Based Translocation Testing
  • Table 9.4: Product Portfolio: NGS-Based Mutation Testing
  • Table 9.5: Product Portfolio: NGS-Based Minimal Residual Disease
  • Table 13.1: Quest Diagnostics Incorporated Product Portfolio
  • Table 13.2: Competitive Portfolio of Opko Health OnkoSight with Other Standard Counterparts in the U.S. hematologic Malignancies Market

List of Figures

  • Figure 1: Estimated New Cases of Hematologic Malignancies in 2020
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the U.S. Hematologic Testing Market
  • Figure 3: Key Strategies Incorporated by Stakeholders of U.S. Hematologic Testing Market to Sustain the Competition (from January 2016 to December 2019)
  • Figure 4: Dominating Segments of the U.S. Hematologic Malignancies Testing Market, 2019 and 2025
  • Figure 5: U.S. Hematologic Malignancies Testing (by Product), 2019 and 2025
  • Figure 6: NGS Based U.S. Hematologic Malignancies Testing (by Product), 2019 and 2025
  • Figure 7: U.S. Hematologic Malignancies Testing Market (by Technology), 2019 and 2025
  • Figure 8: U.S. Hematologic Malignancies Testing Market (by End-User, 2019 and 2025)
  • Figure 2.1: U.S. Hematologic Malignancies Testing Market Segmentation
  • Figure 3.1: U.S. Hematologic Malignancies Testing Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Relative Percent of New Hematological Malignancies Expected to be Reported in U.S. in 2020
  • Figure 4.2: Relative Percent of New Cases Lymphomas Expected in U.S. in 2020
  • Figure 4.3: Relative Percent of New Cases of Leukemias in U.S. in 2020
  • Figure 4.4: Prevalence of Different Hematological Malignancies across U.S. ( 2013-2017)
  • Figure 4.5: State Specfic Prevalence of of Leukemia Across Major U.S. States (2017)
  • Figure 4.6: State Specfic Prevalence of Non-Hodgkin's Lymphoma Across Major U.S. States (2017)
  • Figure 5.1: Relative Prevalence of Non-Hodgkin's Lymphoma & Leukaemia in Midwest U.S. (2017)
  • Figure 5.2: Midwest U.S. Hematologic Malignancies Testing Volume by State, 2019
  • Figure 5.3: Midwest U.S. Hematologic Malignancies Testing Market Size by State (U.S. $ Mn) 2019
  • Figure 5.4: Relative Prevalence of Non-Hodgkin's Lymphoma & Leukemia in Mid-Atlantic U.S. (2017)
  • Figure 5.5: Mid-Atlantic Hematology Malignancies Testing Market Volume by State (2019)
  • Figure 5.6: Mid Atlantic Hematology Malignancies Testing Market Size by State (U.S. $Mn) (2019)
  • Figure 5.7: Relative Prevalence of Non-Hodgkin's Lymphoma & Leukemia in Southwest U.S. by State (2017)
  • Figure 5.8: Southwest U.S. Hematologic Malignancies Testing Volume by State, 2019
  • Figure 5.9: Southwest U.S. Hematologic Malignancies Testing Market Size by State ($ Mn) 2019
  • Figure 5.10: Relative Prevalence of Non-Hodgkin's Lymphoma & Leukemia in New England, by State (2017)
  • Figure 5.11: New England Hematology Malignancies Testing Volume by State, 2019
  • Figure 5.12: New England Hematology Malignancies Testing Market Size by State ($Mn) 2019
  • Figure 5.13: Relative Prevalence of Non-Hodgkin's Lymphoma & Leukemia in the West U.S. (2017)
  • Figure 5.14: The West U.S. Hematologic Malignancies Testing Volume by State, 2019
  • Figure 5.15: West U.S. Hematologic Malignancies Testing Market Size by State (USD Mn) 2019
  • Figure 5.16: Relative Prevalence of Non-Hodgkin's Lymphoma & Leukemia in the South U.S. (2017)
  • Figure 5.17: South U.S. Hematologic Malignancies Testing Volume by State, 2019
  • Figure 5.18: South U.S. Hematologic Malignancies Testing Market Size by State ($ Mn) 2019
  • Figure 6.1: Market Dynamics of U.S. Hematologic Malignancies Testing Market
  • Figure 6.2: Leukemia, U.S. Incident Cases (x1000), (2010-2018)
  • Figure 7.1: Share of Key Developments and Strategies, January 2016 - September 2019
  • Figure 7.2: Synergistic Activities Share (by Companies), January 2016 - September 2019
  • Figure 7.3: Approvals Share (by Companies), January 2016 - September 2019
  • Figure 7.4: Product Launches and Enhancements Share (by Companies), January 2016 - September 2019
  • Figure 7.5: Acquisition and Merger Share (by Companies), January 2016 - September 2019
  • Figure 7.6: Market Share Analysis for the U.S. Hematologic Malignancies Testing Market, 2018
  • Figure 7.7: Growth Share Matrix for U.S. Hematologic Malignancies Testing Market (by company), 2018
  • Figure 7.8: Growth Share Matrix for U.S. Hematologic Malignancies Testing Market (by Product), 2018
  • Figure 8.1: ADLT Parameters
  • Figure 9.1: U.S. Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
  • Figure 9.2: U.S. NGS-Based Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
  • Figure 9.3: U.S. Hematologic Malignancies Testing Services Market, $Million, 2018-2025
  • Figure 9.4: U.S. NGS-Based Hematologic Malignancies Testing Services Market, $Million, 2018-2025
  • Figure 9.5: U.S. Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
  • Figure 9.6: U.S. NGS Based Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
  • Figure 9.7: Gene Panels Market, $Million, 2018-2025
  • Figure 9.8: NGS-Based Gene Panels Leukemia Market, $Million, 2018-2025
  • Figure 9.9: NGS-Based Gene Panels Lymphoma Testing Market, $Million, 2018-2025
  • Figure 9.10: NGS-Based Gene Panels Multiple Myeloma Testing Market, $Million, 2018-2025
  • Figure 9.11: NGS-Based Gene Panels Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
  • Figure 9.12: NGS-Based Gene Panels Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
  • Figure 9.13: NGS-Based Molecular Clonality Testing Market, $Million, 2018-2025
  • Figure 9.14: NGS-Based Molecular Clonality Leukemia Testing Market, $Million, 2018-2025
  • Figure 9.15: NGS-Based Molecular Clonality Lymphoma Testing Market, $Million, 2018-2025
  • Figure 9.16: NGS-Based Molecular Clonality Multiple Myeloma Testing Market, $Million, 2018-2025
  • Figure 9.17: NGS-Based Molecular Clonality Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
  • Figure 9.18: NGS-Based Molecular Clonality Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
  • Figure 9.19: NGS-Based Translocation Testing Market, $Million, 2018-2025
  • Figure 9.20: NGS-Based Translocation Leukemia Testing Market, $Million, 2018-2025
  • Figure 9.21: NGS-Based Translocation Lymphoma Testing Market, $Million, 2018-2025
  • Figure 9.22: NGS-Based Molecular Clonality Multiple Myeloma Testing Market, $Million, 2018-2025
  • Figure 9.23: NGS-Based Translocation Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
  • Figure 9.24: NGS-Based Translocation Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
  • Figure 9.25: NGS-Based Mutation Testing Market, $Million, 2018-2025
  • Figure 9.26: NGS-Based Mutation Leukemia Testing Market, $Million, 2018-2025
  • Figure 9.27: NGS-Based Mutation Lymphoma Testing Market, $Million, 2018-2025
  • Figure 9.28: NGS-Based Mutation Multiple Myeloma Testing Market, $Million, 2018-2025
  • Figure 9.29: NGS-Based Mutation Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
  • Figure 9.30: NGS-Based Mutation Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
  • Figure 9.31: NGS-Based Minimal Residual Disease (MRD) Testing Market, $Million, 2018-2025
  • Figure 9.32: NGS-Based MRD Leukemia Market, $Million, 2018-2025
  • Figure 9.33: NGS-Based Translocation Lymphoma Testing Market, $Million, 2018-2025
  • Figure 9.34: NGS-Based Minimal Residual Disease Multiple Myeloma Testing Market, $Million, 2018-2025
  • Figure 9.35: NGS-Based Minimal Residual Disease Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
  • Figure 9.36: NGS-Based Minimal Residual Disease Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
  • Figure 10.1: U.S. Hematologic Malignancies Testing Market (by End User), 2019 vs 2025
  • Figure 10.2: Specialty Clinics and Hospitals Market, $Million, 2018-2025
  • Figure 10.3: Diagnostic Laboratories Market, $Million, 2018-2025
  • Figure 10.4: Reference Laboratories Market, $Million, 2018-2025
  • Figure 10.5: Research Institutions Market, $Million, 2018-2025
  • Figure 11.1: U.S. Hematologic Malignancies Testing Market (by Disease), 2019 vs 2025
  • Figure 11.2: U.S. Leukemia Testing Market, $Million, 2018-2025
  • Figure 11.3: U.S. Lymphoma Testing Market, $Million, 2018-2025
  • Figure 11.4: U.S. Multiple Myeloma Testing Market, $Million, 2018-2025
  • Figure 11.5: U.S. Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
  • Figure 11.6: U.S. Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
  • Figure 12.1: U.S. Hematologic Malignancies Testing Market (by Technology), 2019 vs 2025
  • Figure 12.2: U.S. Hematologic Malignancies Testing Market by NGS, $Million, 2018-2025
  • Figure 12.3: U.S. Hematologic Malignancies Testing Market by PCR, $Million, 2018-2025
  • Figure 12.4: U.S. Hematologic Malignancies Testing Market by FISH, $Million, 2018-2025
  • Figure 12.5: U.S. Hematologic Malignancies Testing Market by Immunohistochemistry, $Million, 2018-2025
  • Figure 12.6: U.S. Hematologic Malignancies Testing Market by Flow Cytometry, $Million, 2018-2025
  • Figure 12.7: U.S. Hematologic Malignancies Testing Market by Other Technologies, $Million, 2018-2025
  • Figure 13.1: Total Number of Companies Profiled
  • Figure 13.2: Abbott Laboratories: Overall Product Portfolio
  • Figure 13.3: Abbott Laboratories: Overall Financials, 2016-2018
  • Figure 13.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
  • Figure 13.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
  • Figure 13.6: Abbott Laboratories: Revenue (by Region), 2016-2018
  • Figure 13.7: Abbott Laboratories: R&D Expenditure, 2016-2018
  • Figure 13.8: Abbott Laboratories: SWOT Analysis
  • Figure 13.9: Illumina, Inc.: Overall Product Portfolio
  • Figure 13.10: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 13.11: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 13.12: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 13.13: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 13.14: Illumina, Inc.: SWOT Analysis
  • Figure 13.15: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 13.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 13.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
  • Figure 13.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
  • Figure 13.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 13.20: F. Hoffmann-La Roche: SWOT Analysis
  • Figure 13.21: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 13.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
  • Figure 13.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2016-2018
  • Figure 13.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
  • Figure 13.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
  • Figure 13.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 13.27: Sysmex Corporation: Overall Product Portfolio
  • Figure 13.28: Sysmex Corporation: Overall Financials, 2016-2018
  • Figure 13.29: Sysmex Corporation: Sales (by Segment), 2016-2018
  • Figure 13.30: Sysmex Corporation: Sales (by Region), 2016-2018
  • Figure 13.31: Sysmex Corporation: R&D Expenditure, 2016-2018
  • Figure 13.32: Sysmex Corporation: SWOT Analysis
  • Figure 13.33: ASURAGEN, INC.: Overall Product Portfolio
  • Figure 13.34: ASURAGEN, INC.: SWOT Analysis
  • Figure 13.35: Product Portfolio: Cancer Genetics Inc.
  • Figure 13.36: Cancer Genetics Inc.: Overall Financials, 2016-2018
  • Figure 13.37: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
  • Figure 13.38: Cancer Genetics Inc.: Sales (by Region), 2016-2018
  • Figure 13.39: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
  • Figure 13.40: Cancer Genetics Inc.: SWOT Analysis
  • Figure 13.41: QIAGEN N.V.: Overall Product Portfolio
  • Figure 13.42: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 13.43: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 13.44: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 13.45: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 13.46: QIAGEN N.V.: SWOT Analysis
  • Figure 13.47: ArcherDX, Inc.: Overall Product Portfolio
  • Figure 13.48: ArcherDX, Inc.: SWOT Analysis
  • Figure 13.49: Adaptive Biotechnologies: Overall Product Portfolio
  • Figure 13.50: Adaptive Biotechnologies: SWOT Analysis
  • Figure 13.51: ICON plc: Overall Product Portfolio
  • Figure 13.52: ICON plc: Overall Financials, 2016-2018
  • Figure 13.53: ICON plc: Revenue (by Region), 2016-2018
  • Figure 13.54: ICON plc: SWOT Analysis
  • Figure 13.55: Quest Diagnostics Incorporated: Overall Product Portfolio
  • Figure 13.56: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
  • Figure 13.57: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2016 - 2018
  • Figure 13.58: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 13.59: ARUP Laboratories: Overall Product Portfolio
  • Figure 13.60: ARUP Laboratories: SWOT Analysis
  • Figure 13.61: Invivoscribe, Inc.: Overall Product Portfolio
  • Figure 13.62: Invivoscribe, Inc.: SWOT Analysis
  • Figure 13.63: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
  • Figure 13.64: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
  • Figure 13.65: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2016-2018
  • Figure 13.66: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2016-2018
  • Figure 13.67: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 13.68: Invitae Corporation: Overall Product Portfolio
  • Figure 13.69: Invitae Corporation: Overall Financials, 2016-2018
  • Figure 13.70: Invitae Corporation: Revenue (by Segment), 2016-2018
  • Figure 13.71: Invitae Corporation: Revenue (by Geography), 2016-2018
  • Figure 13.72: Invitae Corporation: R&D Expenditure, 2016-2018
  • Figure 13.73: Invitae Corporation: SWOT Analysis
  • Figure 13.74: Opko Health: Overall Services Portfolio
  • Figure 13.75: Opko Health: Overall Financials, 2016-2018
  • Figure 13.76: Opko Health: Revenue (by Segment), 2016-2018
  • Figure 13.77: Opko Health: R&D Expenditure, 2016-2018
  • Figure 13.78: Opko Health: SWOT Analysis
  • Figure 13.79: Laboratory Corporation of America Holdings: Overall Services Portfolio
  • Figure 13.80: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
  • Figure 13.81: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
  • Figure 13.82: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
  • Figure 13.83: Laboratory Corporation of America Holdings: SWOT Analysis